ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
119.624,51
-1,27%
S&P 500
5.918,25
0,16%
US Dollar vs BRL
6,10615
-0,02%
Bitcoin
94.287,33
-0,81%
Brent Oil
75,83
-0,21%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Prelude Therapeutics Inc (PRLD)

  7. Prelude Therapeutics Inc (PRLD) Notícias

PRLD

Prelude Therapeutics (PRLD)

Prelude Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRLD
DataHoraFonteTítuloCódigoCompanhia
07/01/202518:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202409:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PRLDPrelude Therapeutics Inc
11/12/202409:30GlobeNewswire Inc.Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid MalignanciesNASDAQ:PRLDPrelude Therapeutics Inc
27/11/202409:30GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology SummitNASDAQ:PRLDPrelude Therapeutics Inc
06/11/202418:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PRLDPrelude Therapeutics Inc
06/11/202418:05GlobeNewswire Inc.Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
24/10/202408:30GlobeNewswire Inc.Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR SymposiumNASDAQ:PRLDPrelude Therapeutics Inc
09/10/202408:30GlobeNewswire Inc.Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR SymposiumNASDAQ:PRLDPrelude Therapeutics Inc
13/09/202411:00GlobeNewswire Inc.Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 TrialNASDAQ:PRLDPrelude Therapeutics Inc
09/09/202408:30GlobeNewswire Inc.Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/08/202408:01GlobeNewswire Inc.Prelude Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
09/07/202408:30GlobeNewswire Inc.Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated CancersNASDAQ:PRLDPrelude Therapeutics Inc
11/06/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PRLDPrelude Therapeutics Inc
03/06/202408:01GlobeNewswire Inc.Prelude Therapeutics to Participate in Upcoming Healthcare ConferencesNASDAQ:PRLDPrelude Therapeutics Inc
30/05/202417:29Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PRLDPrelude Therapeutics Inc
16/05/202417:09Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/05/202408:01GlobeNewswire Inc.Prelude Therapeutics to Participate in Citizens JMP Life Sciences ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
07/05/202408:01GlobeNewswire Inc.Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:PRLDPrelude Therapeutics Inc
06/05/202417:24Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
09/04/202417:35GlobeNewswire Inc.Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
05/03/202418:45GlobeNewswire Inc.Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual MeetingNASDAQ:PRLDPrelude Therapeutics Inc
29/02/202418:05GlobeNewswire Inc.Prelude Therapeutics to Participate in Barclays Global Healthcare ConferenceNASDAQ:PRLDPrelude Therapeutics Inc
15/02/202419:22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PRLDPrelude Therapeutics Inc
15/02/202418:05GlobeNewswire Inc.Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024NASDAQ:PRLDPrelude Therapeutics Inc
12/02/202418:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PRLDPrelude Therapeutics Inc
11/12/202311:34GlobeNewswire Inc.Prelude Therapeutics Announces $25 Million Private PlacementNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202317:10GlobeNewswire Inc.Prelude Announces Strategic Pipeline Progress and Updates, including its Partnership with AbCellera, and Reports Third Quarter Financial ResultsNASDAQ:PRLDPrelude Therapeutics Inc
01/11/202317:05GlobeNewswire Inc.Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in OncologyNASDAQ:PRLDPrelude Therapeutics Inc
14/10/202313:30GlobeNewswire Inc.Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference NASDAQ:PRLDPrelude Therapeutics Inc
29/08/202309:30GlobeNewswire Inc.Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in SeptemberNASDAQ:PRLDPrelude Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PRLD

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
AZEV4
AZEVEDO PN
BOV
PMAM3
PARANAPANEMA ON
BOV
BHIA3
Grupo Casas Bahia ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
MNPR3
MINUPAR ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados